Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on June 21, 2007
Japanese Journal of Clinical Oncology 2007 37(6):469-472; doi:10.1093/jjco/hym046
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/6/469    most recent
hym046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Morita, S.
Right arrow Articles by Sakamoto, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morita, S.
Right arrow Articles by Sakamoto, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

A Randomized Phase II Selection Trial in Patients with Advanced/Recurrent Gastric Cancer: Trial for Advanced Stomach Cancer (TASC)

Satoshi Morita1,, Hideo Baba2, Akira Tsuburaya3, Hiroya Takiuchi4, Takanori Matsui5, Yoshihiko Maehara6 and Junichi Sakamoto1

1 Department of Medical Administration, Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya
2 Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
3 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama
4 Second Department of Internal Medicine, Osaka Medical College, Osaka
5 Department of Clinical Research, Aichi Cancer Center Aichi Hospital, Aichi
6 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

For reprints and all correspondence: Satoshi Morita, Department of Medical Administration, Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-Ku, Nagoya, 466-8550, Japan. E-mail: smorita{at}med.nagoya-u.ac.jp

Received December 15, 2006; accepted January 28, 2007

A randomized phase II clinical trial is being conducted for patients with advanced or recurrent gastric cancer, in order to select the most promising treatment for subsequent evaluation in a large-scale phase III trial. We compare four chemotherapeutic treatments, which include two sequential and two combination regimens using paclitaxel with 5-fluorouracil or S-1, an oral fluorouracil derivative. The primary endpoint is 10-month overall survival rate, while the secondary endpoints are adverse events, time to treatment failure and progression-free survival. A Bayesian method is used to provide a statistical rule for monitoring the trial. Forty patients per treatment regimen (160 in total) were randomized into one of the four regimens using a centralized dynamic method.

Key Words: Randomized phase II trial • gastric cancer • chemotherapy • Bayesian trial monitoring


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.